Optimi Health is a Canadian pharmaceutical manufacturer producing GMP-certified MDMA and psilocybin capsules for prescription use. The company focuses on psychedelic-assisted therapy for conditions like post-traumatic stress disorder and treatment-resistant depression. Optimi holds a Health Canada Drug Establishment Licence, which enables the manufacture and international export of controlled substances as finished drug products. This regulatory status allows Optimi to supply the Australian market through an exclusive distribution agreement with KMT Pharmaceuticals. In Canada, the company provides products through the Special Access Program and supplies third-party clinical trials in Israel and Canada. Optimi operates a vertically integrated model, cultivating mushrooms and extracting active ingredients at its facilities in British Columbia to maintain quality and cost control. The company generates revenue by selling finished capsules to distributors, authorized prescribers, and clinical trial sponsors. Growth depends on regulatory shifts in international markets, with current expansion efforts focused on Australia and Israel while preparing for potential entry into the United States. Optimi aims to improve margins by scaling production and automating its manufacturing processes.